Clinical trials: Attention Deficit Disorders With Hyperactivity
ADHD
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
This study is a multicenter, dose-optimized, open-label safety study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT03460652
- Testing
- KP415 oral capsule
- Where
- 19 sites in United States
- Volunteers
- 282 people
- Sponsor
- Zevra Therapeutics
Attention Deficit Hyperactivity Disorder
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder characterized by lifelong issues of inattention, distraction, organizational difficulties, forgetfulness, restlessness, talking out of turn, difficulty…
- Trial name
- ADD201 (NCT00983814)
- Testing
- Droxidopa+Carbidopa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Chelsea Therapeutics
Attention Deficit Hyperactivity Disorder
Intervention for Teens With ADHD and Substance Use
Individuals with ADHD are at markedly high risk for increased substance use and Substance Use Disorder (SUD). Given the strong evidence for the negative trajectory of individuals with co-occurring ADHD and substance use…
- Trial name
- NCT02502799
- Testing
- Brief Early Intervention, Parent Training with Adolescent Cognitive Behavioral Therapy, Methylphenidate
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Florida International University
ADHD, Autism
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
The purpose of this study is to determine whether Quillivant XR is effective in the treatment of ADHD in children with Autism Spectrum Disorder (ASD).
- Trial name
- NCT02255565
- Testing
- Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Seattle Children's Hospital
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
ADHD
SPD544 High Strength Bioequivalence Study
The purpose of this study is to assess bioequivalence of 2 capsule strengths.
- Trial name
- NCT01183234
- Testing
- SPD544, Methylphenidate hydrochloride
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder (ADHD)
Trigeminal Nerve Stimulation for ADHD
The purpose of this study is to develop external Trigeminal Nerve Stimulation (eTNS) as a potential nonmedication treatment for attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- TNS for ADHD (NCT02155608)
- Testing
- Active eTNS
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, Los Angeles
Attention Deficit Hyperactivity Disorder
Investigation of Strategies to Reduce the Impact of the Relative Age Effect in Kindergarten
There is now clear evidence that children entering kindergarten, that are relatively young for the grade (e.g., born in the months immediately preceding the school entry cut-off) are at significantly more risk for receiving an…
- Trial name
- NCT05142826
- Testing
- Relative Age Effect Intervention, School as Usual
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Florida International University
Attention Deficit Disorder With Hyperactivity
Neuroimaging of the Effects of Concerta in the Treatment of ADHD
A number of brain regions have been down to be altered in both structure and function in patients with ADHD, including prefrontal cortex, anterior cingulate, caudate and cerebellum.
- Trial name
- NCT00778310
- Testing
- methylphenidate-OROS
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
ADHD
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD
- Trial name
- NCT02139124
- Testing
- PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg
- Where
- 38 sites in United States, Canada
- Volunteers
- 375 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
ADHD
Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention
There has been an increasing focus on the adverse impacts of irritability, defined as increased tendency towards anger. Irritability worsens peer relationships, family functioning, academic performance and is a risk factor for…
- Trial name
- NCT03279952
- Testing
- CNS Stimulant
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Milton S. Hershey Medical Center
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01552915
- Testing
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride
- Where
- 79 sites in United States
- Volunteers
- 464 people
- Sponsor
- Shire
Attention Deficit Disorder With Hyperactivity (ADHD)
Transcranial Magnetic Stimulation for Attention Deficit/Hyperactivity Disorder (ADHD)
This study will test the effects of transcranial magnetic stimulation (TMS) on clinical measures of ADHD symptoms.
- Trial name
- NCT03663179
- Testing
- Transcranial Magnetic Stimulation (TMS)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Pennsylvania
Intermittent Explosive Disorder, Childhood Aggression
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Children with explosive aggression are often rejected by their peers, placed in special classroom, and contribute to family discord. When psychotherapy and family therapy is unsuccessful, medications are often used.
- Conditions
- Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
- Trial name
- NCT02048241
- Testing
- Parent Management Training, Intuniv
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- New York State Psychiatric Institute
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder
An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).
The study is a phase IIIb multicentre, randomised, placebo controlled, trial in paediatric patients with Attention-Deficit/Hyperactivity (ADHD) and Oppositional Defiant Disorder (ODD).
- Trial name
- NCT00192023
- Testing
- atomoxetine 0.5 mg/kg/day, atomoxetine 1.2 mg/kg/day, atomoxetine 1.2-1.4 mg/kg/day
- Where
- 12 sites in Italy
- Volunteers
- 139 people
- Sponsor
- Eli Lilly and Company
Attention-Deficit Hyperactivity Disorder (ADHD)
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
A study to evaluate the efficacy and safety of dasotraline in children 6 years of age to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.
- Trial name
- NCT02734693
- Testing
- dasotraline 4mg
- Where
- 5 sites in United States
- Volunteers
- 132 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder
Improving Sleep and Daytime Functioning Among Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)
This study will test the efficacy of a systematic, multi-modal intervention protocol designed to improve sleep functioning and subsequent alleviation of daytime cognitive and behavioral difficulties among children diagnosed with…
- Trial name
- NCT00867451
- Testing
- Sleep Intervention, Melatonin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder
Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials
The purpose of this research study is to study a device called an electroencephalograph (EEG) in the diagnosis of treatment of attention deficit hyperactivity disorder (ADHD) in adults.
- Trial name
- NCT01063153
- Testing
- Osmotic Release Methylphenidate
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
This was a Phase 2b, randomized, double-blind, multicenter, 2-period, 2-treatment, crossover study to evaluate safety and efficacy of CTN SR compared with placebo in adults with ADHD.
- Trial name
- NCT02547428
- Testing
- CTN SR
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.